Investing in the stock market can be a rollercoaster of emotions. One company that has recently caught my eye in the FTSE 100 is pharmaceutical giant GSK. Despite its recent struggles, there may be an opportunity to capitalize on its downturn.
- Challenges Facing GSK
GSK has been grappling with the need to replenish its drugs pipeline since CEO Emma Walmsley took the helm in 2017. This demand for innovation and development has seen dividend payments dwindle, a move aimed at funding research efforts. However, the anticipated fruits of these investments are yet to materialize, leaving many investors disillusioned.
- Historical Performance
Once considered a stronghold of dividend stocks, GSK has seen a decline in its share price and dividend yield over the years. The recent drop in share prices may present an opportunity for investors looking to capitalize on its potential upturn. The share prices have been volatile, with intermittent spikes followed by subsequent declines, leaving long-term investors disappointed.
- Recent Setbacks
This year, GSK faced a series of setbacks, including a class action lawsuit in the US over its heartburn treatment, Zantac. In addition, political uncertainty in the US under the Trump administration has cast a shadow of doubt over the pharmaceutical industry. The appointment of a vaccine skeptic and proposals to lower drug prices added to the uncertainty surrounding GSK’s future.
- Conclusion
Despite its recent challenges, GSK remains an intriguing prospect for investors. With analysts projecting a potential 30% increase in share prices, there may be room for growth in the future. However, given the uncertainties surrounding the pharmaceutical industry, a cautious approach seems prudent. Holding onto existing investments while refraining from further commitments might be a sensible strategy for the time being. As the pharmaceutical giant navigates through its current turmoil, investors should keep a watchful eye on GSK’s future prospects.
Leave feedback about this